News

Cubist Pharma said that the increase was attributable primarily to its net sales of Cubicin (daptomycin for injection) in the US, which increased 23% to $155m from $126.1m

Emergent said that its Baltimore manufacturing facility could create an additional 120 jobs in the next five years. Emergent is currently working on modifying and re-commissioning the facility.

Merz Aesthetics said that Asclera was shown to be effective in treating sclerotherapy, in a study published in the June issue of Phlebology. Merz Aesthetics’ Asclera was approved

Novartis’ operating income rose 25% to $3bn, compared to $2.4bn for the comparable period in 2009. Earnings per share (EPS) increased 18% to $1.06 while core EPS was

Noscira claimed that Phase IIa trial, which was conducted at three centres in Germany considering an advice from experts at the European Medicines Agency (EMA), is the first

The drug development work is supported by a Seeding Drug Discovery Award from the Wellcome Trust, to a team of researchers led by David Wynick, professor of molecular

AVI-6002 and AVI-6003 are RNA-based therapeutic candidates from AVI’s anti-infective portfolio and use its proprietary PMOplus chemistry. The current contract is funded as part of the Transformational Medical

MediTouch is an EHR used by physicians and is designed for practices of all sizes. HealthFusion claimed that the software offers intuitive and touch screen charting interface and

Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures for adults; infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, myoclonic,